NicOx files anti-inflammatory naproxcinod for osteoarthritis in EU
This article was originally published in Scrip
Executive Summary
NicOx has filed its lead compound, the anti-inflammatory naproxcinod, for the relief of the signs and symptoms of osteoarthritis in Europe. The drug has already been filed in the US, where it has a PDUFA date of July 24th, 2010.